Lille Cedex

• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Ended recruitment
  2024-513521-23-00 5 2015-08-19 Prostate Cancer
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment
  2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence
• IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac … Halted
  2024-517254-99-00 4 2025-09-16 The patients enrolled in IMMUNORARE will be adult patients with 5 rar
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404 … Halted
  2023-505096-68-00 4 2025-01-14 Preclinical Alzheimer’s Disease
• Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer Halted
  2024-515996-37-00 3 2021-07-30 peritoneal carcinosis of ovarian origin cancer
• MIVAR - Milrinone Infusion for VAsospam treatment in subarachnoid hemoRrhage Ended
  2024-515994-83-00 5 2026-01-13 aneurysmal subarachnoid hemorrhage with a vasospasm
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• Characterization of Immune Response in Participants from a Posdinemab Study Ended
  2024-514634-20-00 3 2025-02-25 Early Alzheimer's disease
• Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver Ended
  2024-517751-13-01 4 2024-12-26 Psychiatric disorders
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin … Ended
  2024-516435-27-00 4 2024-11-05 High-risk myeloïd malignancies
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 5 2024-10-21 Thyroid Eye Disease (TED)
• Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular car … Ended
  2024-516408-40-00 9 2024-10-14 Non-resectable hepatocellular carcinoma (HCC)
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 4 2024-09-09 Patients displaying a non-classified, severe and resistant inflammator
• Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended
  2024-516299-13-00 4 2024-09-06 Resectable Gastric Cancer
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 4 2024-08-14 Migraine
• A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec … Ended
  2023-505086-83-00 4 2024-07-10 Tourette Syndrome
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Pat … Ended
  2023-506976-28-00 9 2024-05-16 Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• Short-term GnRH- Antagonist Treatment to Lower LH Pulsatility in Women With PCOS Aiming to Improve Hormonal Functions - SOPKGANI Ended
  2024-514102-32-00 1 2024-04-17 Polycystic ovarian

Showing 553–576 of 681 trials